COVID-19 mRNA booster vaccines elicit strong protection against SARS-CoV-2 Omicron variant in patients with cancer
- 30 December 2021
- journal article
- letter
- Published by Elsevier in Cancer Cell
- Vol. 40 (2) , 117-119
Abstract
No abstract availableAll Related Versions
Funding Information
- National Institutes of Health (R01 AI150473)
- National Cancer Institute
This publication has 8 references indexed in Scilit:
- Neutralization of SARS-CoV-2 Omicron sub-lineages BA.1, BA.1.1, and BA.2Cell Host & Microbe, 2022
- Omicron SARS-CoV-2 variant: a new chapter in the COVID-19 pandemicThe Lancet, 2021
- Impaired neutralizing antibody response to COVID-19 mRNA vaccines in cancer patientsCell & Bioscience, 2021
- Efficacy of booster doses in augmenting waning immune responses to COVID-19 vaccine in patients with cancerCancer Cell, 2021
- Resurgence of SARS-CoV-2 Infection in a Highly Vaccinated Health System WorkforceNew England Journal of Medicine, 2021
- Anti-spike antibody response to SARS-CoV-2 booster vaccination in patients with B cell-derived hematologic malignanciesCancer Cell, 2021
- Age-related immune response heterogeneity to SARS-CoV-2 vaccine BNT162b2Nature, 2021
- Neutralizing antibody against SARS-CoV-2 spike in COVID-19 patients, health care workers, and convalescent plasma donorsJCI Insight, 2020